Home » Topics » BioWorld Science

BioWorld Science
RSS

Plenaxis commercialization and development progress

May 26, 2004

Initial NICE recommendations for Glivec rebutted by Novartis

May 26, 2004

AstraZeneca confirms safety of Crestor

May 26, 2004

Nadixa launched in Germany

May 26, 2004

Additional analysis of response data from phase III Dacogen study in MDS

May 26, 2004

Sinovac Biotech commences phase I testing of SARS vaccine

May 26, 2004

Approval letter for anidulafungin

May 26, 2004

Ketek 99% effective in vitro against S. pneumoniae bacteria

May 26, 2004

Genetronics and Merck in agreement for MedPulser DNA Delivery System

May 26, 2004

New European phase III trial for Zadaxin triple therapy in HCV

May 26, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...